Table 2.
Treatment | Exp. 1 | Exp. 2 | Exp. 3 | Exp.4 | Exp. 5 | Exp. 6 | Average | SD |
---|---|---|---|---|---|---|---|---|
Basal | 47.6 | 54.4 | 47.5 | 50.4 | 38.6 | 46 | 47.4 | 5.2 |
NAC | 64.6 | N/A | 38.4 | 51.5 | 38 | 39.5 | 46.4 | 10.4 |
BSO | N/A | 47 | 41.4 | 43.9 | 39.9 | 36.5 | 41.7 | 3.6 |
CHO, Chinese hamster ovary; GSH, glutathione; NAC, N-acetylcysteine; BSO, l-buthionine-sulfoximine
Fractions of ERroGFP1-iL in reduced form (%) in cells before (basal) and after treatment with either 5 mmol/L NAC or 0.1 mmol/L BSO (BSO) were determined as described in Materials and methods. Data for each experiment were collected by flow cytometry and represent an average of three replicates collected on 10,000 cells±SD